VEGFA and glioblastoma: Regarding the vascular microenvironment in GBM, there has been emerging evidence [8,9,10,11,12,13]; as GBM is known to secrete vascular endothelial growth factor (VEGF) and actively induce angiogenesis, Bevacizumab (Bev; an anti-VEGF humanized monoclonal antibody) has recently been used to treat GBM.